United States · FDA National Drug Code directory
Arexvy
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 58160-882_ed295307-eb7c-42c3-80a2-080a316c8954
- Product NDC
- 58160-882
- Form
- KIT
- Composition / generic term
- Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted
- Labeler
- GlaxoSmithKline Biologicals SA
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260430
- Source listing expiry
- 20271231
Source-listed ingredients
Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.
These values do not establish equivalence or a dose recommendation.
Packages
- 1 KIT in 1 CARTON (58160-882-12) * .5 mL in 1 VIAL (58160-719-03) * .5 mL in 1 SYRINGE (58160-749-07) · 58160-882-12
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →